Member Info for Natdan

At least the projected revenue figures are included on this occasion, but the traction gained by the deal and the ability to sell and grow further afield is of far greater benefit and value. The snowball rolling down the hill effect.

As stated earlier, this appears an extension of an existing arrangement with that specific hospital, but using the new platform/kit.
The value of the deal is dependent upon the take-up, so not possible to value. Benefit is the publicity and impetus for some of the many dinosaur NHS trusts to hop on board.

For those long-sufferers here, this brings with it a touch of deja-vu: is it really March 2015 since the first tie-up with St George?
Good news nonetheless, but all eyes still on Covid- testing.

Notaflipper, I do value your contributions here but ppplease, don't take the moral highground.
The point I was making is that should an employee divulge info. or opinions not shared with the Co., serious disciplinary action might be an option.
If you don't like a particular line you always have options to ignore/ delete. Don't endanger posters if you would be so kind.

Most unhelpful to speculate whether an employee/ employers contribute to this site. Only likely outcome would be for such a participant to withdraw. There is a really decent amount of knowledge on this site, best protected by maintaining the anonymity, combined with a decent helping of dyor.

Yeah it's my birthday, a landmark one I don't care to be reminded of.
So a stonking update to take my mind off matters would go down a treat.

Twix surprised you still here- following your own previous investment mantras thought you would have been out by now.
Doom and gloom to boooom reevaluation?

Yet another example of cronyism regarding appointments with the forthcoming Moonshot dream.
Hot on the heels of the likes of Dido Harding, Boris Johnson brother Max and Owen Patterson ( Randox), step forward Mike Coupe, he of the Sainsburys "we're in the money..." fame at the time of the failed merger with Asda.
He becomes responsible for all testing by the end of October. By pure coincidence Harding also worked at Sainsburys at the same time as Coupe, though not believed to be stacking shelves.
This is the murky world LR has to negotiate through and may explain why Ygen appears correctly to have positioned itself primarily towards the corporate market.
Some serious washing of hands on the entire Track 'n' Trace fiasco urgently required.

Sheep, hope you won't mind me mentioning it but this is the Ygen board, and am sure the posters on VAL will love to hear tales of your investing prowess there rather than here. I thank you.

A man of his business word, LR is certainly concentrating on the core business.
By creating "a global laboratory service network" the plan seems to be to pull the various strands together into the one-stop-shop concept for potential clients.
World domination next in progressive leaps and bounds ( also ultimately easier for the inevitable trade sale in the future).

Whiling away an idle moment waiting for a train connection yesterday, I happened across a coy of something called The Daily Mirror, a publication I am hardly familiar with.
Imagine my surprise when I alighted across a Covid-testing story involving an obscure Cheshire-based private company, goes under the name of REVIV Global.
Well, blow me down, the Co. has just appointed as director a brother of no-less than our very own PM, name of Max Johnson. Lives in Asia apparently, bit of a distance from Cheshire if you ask me.
No matter, them Zoom connections are amazing nowadays I hear.
Anyway, the journo done a splendid job by speaking to two of the Co.directors. The first, a Dr. M. Barnish (without any Varnish) openly opined that the appointment could hopefully "open doors".
You bet! The Co. Is coincidentally offering private Covid-19 antigen tests at £89 each. The Dr appeared to be in the know that talks [with the nhs] had occurred with his CEO, and the giveaway "and obviously Max Johnson,etcetera...there are talks going on."
The second was a more formal CEO, a certain Ms Lomas who in a statement asserted "His familial connection to the UK Prime Minister does not give REVIV an advantage..." Played with a straight face one assumes.
The moral to this story is that it shows the fierce competition Ygen is up against as previously diverse companies with so much as a test-tube and a pipette in their armoury sniff the potential of the Moonshot/Moonshine riches.

As an aside, just wanted to mention a quote on testing which appears to have slipped under the radar, from Dom Raab being interviewed by Surley Burley on Sky news yesterday.
"The challenge is that the false positive rate is very high: it's only 7% of tests that will be successful in identifying those who actually have the virus."
If true -and setting aside the obscenity of government policy being decided upon such flawed testing and data (garbage in, garbage out)- then is there an opportunity for Ygen to step up to the plate with its vastly superior and accurate products? Licensing to a third party producer perhaps in order to ramp up capacity? Or is this just fantasy-land on my part?

JAdam, now then no sniping -practice what you preach.
Nonsense to cast aspersions against director purchases.
Sometimes you got to be careful what you write and hope it doesn't come back to bite you, especially hen you lack any evidence.
Now, wash your hands for sure.

And in the meantime Mr Market remains on the sidelines decidedly underwhelmed by the numbers 'update' provided yesterday. Six months of corona nonsense in the country and are we really, truly any the wiser where we sit in the grand scheme of the testing scramble -national or international, nhs or private, etc.?
I am not convinced yesterday was the first 'quarterly' we are expecting- end October would fit the timetable, and probably provide much more clarity once the potential deals in the pipeline are or are not completed.

No doubts LR is a charismatic, dynamic leader. Amazing how another of his inputs gets the juices flowing yet again.
For me, though, a couple of observations.
The idea of a Nasdaq listing which will instantly sprinkle its magic dust on our SP is tempting. But, what a cack-handed way of announcing such an intention, the throwaway 'yes' response being missed by many listeners. Accompanied by no rationale, no costings and most noticeably no time-scale or desire to elaborate. A slippery fish thrown to the seals eager to snap up any morcel to satisfy one's appetite?
Secondly, it can reasonably be concluded now that LR failed to make any sales inroads with Covid-testing and the NHS first-time around. Certainly, absolutely no contracts or numbers have been disclosed.
So why is he now chasing the Moonshot pipe-dream of that serial underachiever Hat Man****, in an ever increasingly over-crowded and dynamically changing testing market?
I fully understand his decision to re-position and aim for the corporate market where margins are far more generous. However, with the continual decimation of the economy and travel and leisure in particular, just how many corporates will survive and still be able to afford the quoted prices here for tests?
Now, wash your hands or them military chaps will pay a visit.

Well the Covid news is wholly underwhelming as the tests-per-month figures were already previously pretty much expected. At least it's a contributor to the core business.

A significant (by our standards) rise in the SP over the week of two whole pennies has breathed new optimism for the way forward.
But is the pending agm and following presentation likely to supply the meat on our otherwise bare Covid bones?
Hopefully, but if numbers are to be disclosed as expected, surely a preemptive rns is needed to light the touchpaper.
Some significant purchases over the week provides a modicum of reassurance of things to come.
Just hope LR relaxes his cagey persona and provides some numbers with which analysts can assess and provide forward projections.
A re-rate would be most welcome.

JAdam, are you seriously suggesting that the likes of Dido Harding (Baronness, married to an MP, same Oxford club as Cameron, horsey connections, nightmare head of TalkTalk and Thomas Cook before that, no previous medical expertise, ad nauseum) got the gig as Tester-in-Chief not through merit alone?
Perish the thought.

Just as an aside, whilst browsing in a book shop earlier today, I purchased a book entitled "Big Money" by PG Wodehouse as a fun read.
It was only later I realised this was a defining omen as clear as tea-leaves for what is about to happen here.
Dyor of course in all matters of superstition.

Florida, RE Randox- I referred to the company on Monday following mention on a BBC Radio4 news feature, not suggesting any wrongdoing but pointing out the dispensing of normal tendering rules left the whole process of awarding Covid-related testing contracts opaque and subject to lack of proper scrutiny. Randox was awarded a £133m contract. Does anyone know why and on what basis?
It may be the case that because Ygen perhaps lacks such cosy parliamentary links it has been overlooked. I just don't know, just something to consider.
Anyway here's to better times round the corner....